{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:27Z","timestamp":1787261007520,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Foundation Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101215","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:10:54Z","timestamp":1781827854000},"page":"101215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pneumonitis after chemoradiotherapy and\/or immunotherapy for stage III and IV non-small cell lung cancer is characterized by specific radiologic and quantitative CT features"],"prefix":"10.1016","volume":"60","author":[{"given":"Xander","family":"Verbeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Defraene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"De Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101215_bb0005","author":"IARC"},{"issue":"Suppl. 4","key":"10.1016\/j.ctro.2026.101215_bb0010","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101215_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdj117","article-title":"Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients","volume":"17","author":"Aup\u00e9rin","year":"2006","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ctro.2026.101215_bb0020","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101215_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101215_bb0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101215_bb0035","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101215_bb0040","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101215_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","article-title":"Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer","volume":"4","author":"Nishino","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.ctro.2026.101215_bb0050","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2026.101215_bb0055","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101215_bb0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ctro.2026.101215_bb0065","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"Radiographics"},{"issue":"2","key":"10.1016\/j.ctro.2026.101215_bb0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccm.2016.12.004","article-title":"Radiation pneumonitis","volume":"38","author":"Bledsoe","year":"2017","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.ctro.2026.101215_bb0075","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1148\/rg.244035160","article-title":"Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis","volume":"24","author":"Choi","year":"2004","journal-title":"Radiographics"},{"key":"10.1016\/j.ctro.2026.101215_bb0080","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small cell lung cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctro.2026.101215_bb0085","article-title":"Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2","volume":"9","author":"Bradley","year":"2026","journal-title":"ESMO Open"},{"issue":"36","key":"10.1016\/j.ctro.2026.101215_bb0090","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101215_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110837","article-title":"Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: an ESTRO clinical practice guideline","volume":"207","author":"De Ruysscher","year":"2025","journal-title":"Radiother Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2026.101215_bb0100","article-title":"Association between the early discontinuation of durvalumab and poor survival in patients with stage III NSCLC","volume":"2","author":"Shaverdian","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"10.1016\/j.ctro.2026.101215_bb0105","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctro.2026.101215_bb0110","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumor phenotype by noninvasive imaging using a quantitative radiomics approach","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctro.2026.101215_bb0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2015.07.033","article-title":"CT characteristics allow identification of patient-specific susceptibility for radiation-induced lung damage","volume":"117","author":"Defraene","year":"2015","journal-title":"Radiother Oncol"},{"issue":"suppl5","key":"10.1016\/j.ctro.2026.101215_bb0120","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practical guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2026.101215_bb0125","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101215_bb0130","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1186\/s12885-021-08661-3","article-title":"Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis","volume":"21","author":"Yamaguchi","year":"2021","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ctro.2026.101215_bb0135","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101215_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcome","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.ctro.2026.101215_bb0145","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:24:22Z","timestamp":1787257462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S2405630826001102"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101215","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumonitis after chemoradiotherapy and\/or immunotherapy for stage III and IV non-small cell lung cancer is characterized by specific radiologic and quantitative CT features","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101215"}}